229 related articles for article (PubMed ID: 38030626)
21. RING finger nuclear factor RNF168 is important for defects in homologous recombination caused by loss of the breast cancer susceptibility factor BRCA1.
Muñoz MC; Laulier C; Gunn A; Cheng A; Robbiani DF; Nussenzweig A; Stark JM
J Biol Chem; 2012 Nov; 287(48):40618-28. PubMed ID: 23055523
[TBL] [Abstract][Full Text] [Related]
22. ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair.
Chen CC; Kass EM; Yen WF; Ludwig T; Moynahan ME; Chaudhuri J; Jasin M
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):7665-7670. PubMed ID: 28659469
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Nacson J; Krais JJ; Bernhardy AJ; Clausen E; Feng W; Wang Y; Nicolas E; Cai KQ; Tricarico R; Hua X; DiMarcantonio D; Martinez E; Zong D; Handorf EA; Bellacosa A; Testa JR; Nussenzweig A; Gupta GP; Sykes SM; Johnson N
Cell Rep; 2018 Sep; 24(13):3513-3527.e7. PubMed ID: 30257212
[TBL] [Abstract][Full Text] [Related]
24. PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1.
Belotserkovskaya R; Raga Gil E; Lawrence N; Butler R; Clifford G; Wilson MD; Jackson SP
Nat Commun; 2020 Feb; 11(1):819. PubMed ID: 32041954
[TBL] [Abstract][Full Text] [Related]
25. Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Mengwasser KE; Adeyemi RO; Leng Y; Choi MY; Clairmont C; D'Andrea AD; Elledge SJ
Mol Cell; 2019 Mar; 73(5):885-899.e6. PubMed ID: 30686591
[TBL] [Abstract][Full Text] [Related]
26. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors.
Huang F; Goyal N; Sullivan K; Hanamshet K; Patel M; Mazina OM; Wang CX; An WF; Spoonamore J; Metkar S; Emmitte KA; Cocklin S; Skorski T; Mazin AV
Nucleic Acids Res; 2016 May; 44(9):4189-99. PubMed ID: 26873923
[TBL] [Abstract][Full Text] [Related]
27. CtIP-mediated resection is essential for viability and can operate independently of BRCA1.
Polato F; Callen E; Wong N; Faryabi R; Bunting S; Chen HT; Kozak M; Kruhlak MJ; Reczek CR; Lee WH; Ludwig T; Baer R; Feigenbaum L; Jackson S; Nussenzweig A
J Exp Med; 2014 Jun; 211(6):1027-36. PubMed ID: 24842372
[TBL] [Abstract][Full Text] [Related]
28. Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response.
Kelso AA; Lopezcolorado FW; Bhargava R; Stark JM
PLoS Genet; 2019 Aug; 15(8):e1008319. PubMed ID: 31381562
[TBL] [Abstract][Full Text] [Related]
29. Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events.
Mackay DR; Howa AC; Werner TL; Ullman KS
J Cell Sci; 2017 Oct; 130(19):3347-3359. PubMed ID: 28751496
[TBL] [Abstract][Full Text] [Related]
30. Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors.
Ma L; Chen W; Yang M; Ha S; Xiong S; Zhu J; Xiang H; Luo G
J Med Chem; 2024 Mar; 67(5):3606-3625. PubMed ID: 38375763
[TBL] [Abstract][Full Text] [Related]
31. CHAMP1-POGZ counteracts the inhibitory effect of 53BP1 on homologous recombination and affects PARP inhibitor resistance.
Fujita H; Ikeda M; Ui A; Ouchi Y; Mikami Y; Kanno SI; Yasui A; Tanaka K
Oncogene; 2022 May; 41(19):2706-2718. PubMed ID: 35393543
[TBL] [Abstract][Full Text] [Related]
32. Breast Cancer Predisposition Genes and Synthetic Lethality.
Neiger HE; Siegler EL; Shi Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070674
[No Abstract] [Full Text] [Related]
33. Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement.
Lok BH; Powell SN
Clin Cancer Res; 2012 Dec; 18(23):6400-6. PubMed ID: 23071261
[TBL] [Abstract][Full Text] [Related]
34. DNA polymerase θ protects leukemia cells from metabolically induced DNA damage.
Vekariya U; Toma M; Nieborowska-Skorska M; Le BV; Caron MC; Kukuyan AM; Sullivan-Reed K; Podszywalow-Bartnicka P; Chitrala KN; Atkins J; Drzewiecka M; Feng W; Chan J; Chatla S; Golovine K; Jelinek J; Sliwinski T; Ghosh J; Matlawska-Wasowska K; Chandramouly G; Nejati R; Wasik M; Sykes SM; Piwocka K; Hadzijusufovic E; Valent P; Pomerantz RT; Morton G; Childers W; Zhao H; Paietta EM; Levine RL; Tallman MS; Fernandez HF; Litzow MR; Gupta GP; Masson JY; Skorski T
Blood; 2023 May; 141(19):2372-2389. PubMed ID: 36580665
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 Haploinsufficiency Is Masked by RNF168-Mediated Chromatin Ubiquitylation.
Zong D; Adam S; Wang Y; Sasanuma H; Callén E; Murga M; Day A; Kruhlak MJ; Wong N; Munro M; Ray Chaudhuri A; Karim B; Xia B; Takeda S; Johnson N; Durocher D; Nussenzweig A
Mol Cell; 2019 Mar; 73(6):1267-1281.e7. PubMed ID: 30704900
[TBL] [Abstract][Full Text] [Related]
36. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.
Aly A; Ganesan S
J Mol Cell Biol; 2011 Feb; 3(1):66-74. PubMed ID: 21278454
[TBL] [Abstract][Full Text] [Related]
37. 53BP1 Enforces Distinct Pre- and Post-resection Blocks on Homologous Recombination.
Callen E; Zong D; Wu W; Wong N; Stanlie A; Ishikawa M; Pavani R; Dumitrache LC; Byrum AK; Mendez-Dorantes C; Martinez P; Canela A; Maman Y; Day A; Kruhlak MJ; Blasco MA; Stark JM; Mosammaparast N; McKinnon PJ; Nussenzweig A
Mol Cell; 2020 Jan; 77(1):26-38.e7. PubMed ID: 31653568
[TBL] [Abstract][Full Text] [Related]
38. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair.
Kais Z; Rondinelli B; Holmes A; O'Leary C; Kozono D; D'Andrea AD; Ceccaldi R
Cell Rep; 2016 Jun; 15(11):2488-99. PubMed ID: 27264184
[TBL] [Abstract][Full Text] [Related]
39. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
[TBL] [Abstract][Full Text] [Related]
40. 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
Pennington KP; Wickramanayake A; Norquist BM; Pennil CC; Garcia RL; Agnew KJ; Taniguchi T; Welcsh P; Swisher EM
Gynecol Oncol; 2013 Mar; 128(3):493-9. PubMed ID: 23246380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
